Multiple osteochondromas (MO) is an inherited skeletal disorder, and the molecular mechanism of MO remains elusive. Exome sequencing has high chromosomal coverage and accuracy, and has recently been successfully used to identify pathogenic gene mutations. In this study, exome sequencing followed by Sanger sequencing validation was first used to screen gene mutations in two representative MO patients from a Chinese family. After filtering the data from the 1000 Genome Project and the dbSNP database (build 132), the detected candidate gene mutations were further validated via Sanger sequencing of four other members of the same MO family and 200 unrelated healthy subjects. Immunohistochemisty and multiple sequence alignment were performed to evaluate the importance of the identified causal mutation. A novel frameshift mutation, c.1457insG at codon 486 of exon 6 of EXT1 gene, was identified, which truncated the glycosyltransferase domain of EXT1 gene. Multiple sequence alignment showed that codon 486 of EXT1 gene was highly conserved across various vertebrates. Immunohistochemisty demonstrated that the chondrocytes with functional EXT1 in MO were less than those in extragenetic solitary chondromas. The novel c.1457insG deleterious mutation of EXT1 gene reported in this study expands the causal mutation spectrum of MO, and may be helpful for prenatal genetic screening and early diagnosis of MO.
Krooth RS, Macklin MT, Hilbish TF (1961) Diaphysial aclasis (multiple exostoses) on Guam. Am J Hum Genet 13: 340–347.
[3]
Schmale GA, Conrad EU 3rd, Raskind WH (1994) The natural history of hereditary multiple exostoses. J Bone Joint Surg Am 76: 986–992.
[4]
Legeai-Mallet L, Munnich A, Maroteaux P, Le Merrer M (1997) Incomplete penetrance and expressivity skewing in hereditary multiple exostoses. Clin Genet 52: 12–16.
[5]
Hameetman L, Bovee JV, Taminiau AH, Kroon HM, Hogendoorn PC (2004) Multiple osteochondromas: clinicopathological and genetic spectrum and suggestions for clinical management. Hered Cancer Clin Pract 2: 161–173.
[6]
Cook A, Raskind W, Blanton SH, Pauli RM, Gregg RG, et al. (1993) Genetic heterogeneity in families with hereditary multiple exostoses. Am J Hum Genet 53: 71–79.
[7]
Ahn J, Ludecke HJ, Lindow S, Horton WA, Lee B, et al. (1995) Cloning of the putative tumour suppressor gene for hereditary multiple exostoses (EXT1). Nat Genet 11: 137–143.
[8]
Wu YQ, Heutink P, de Vries BB, Sandkuijl LA, van den Ouweland AM, et al. (1994) Assignment of a second locus for multiple exostoses to the pericentromeric region of chromosome 11. Hum Mol Genet 3: 167–171.
[9]
Ligon AH, Potocki L, Shaffer LG, Stickens D, Evans GA (1998) Gene for multiple exostoses (EXT2) maps to 11(p11.2p12) and is deleted in patients with a contiguous gene syndrome. Am J Med Genet 75: 538–540.
[10]
Dobson-Stone C, Cox RD, Lonie L, Southam L, Fraser M, et al. (2000) Comparison of fluorescent single-strand conformation polymorphism analysis and denaturing high-performance liquid chromatography for detection of EXT1 and EXT2 mutations in hereditary multiple exostoses. Eur J Hum Genet 8: 24–32.
[11]
Wuyts W, Van Hul W (2000) Molecular basis of multiple exostoses: mutations in the EXT1 and EXT2 genes. Hum Mutat 15: 220–227.
[12]
Signori E, Massi E, Matera MG, Poscente M, Gravina C, et al. (2007) A combined analytical approach reveals novel EXT1/2 gene mutations in a large cohort of Italian multiple osteochondromas patients. Genes Chromosomes Cancer 46: 470–477.
[13]
Francannet C, Cohen-Tanugi A, Le Merrer M, Munnich A, Bonaventure J, et al. (2001) Genotype-phenotype correlation in hereditary multiple exostoses. J Med Genet 38: 430–434.
[14]
Alvarez C, Tredwell S, De Vera M, Hayden M (2006) The genotype-phenotype correlation of hereditary multiple exostoses. Clin Genet 70: 122–130.
[15]
Wu CH, Fallini C, Ticozzi N, Keagle PJ, Sapp PC, et al. (2012) Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature 488: 499–503.
[16]
Varela I, Tarpey P, Raine K, Huang D, Ong CK, et al. (2011) Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469: 539–542.
[17]
Thompson ER, Doyle MA, Ryland GL, Rowley SM, Choong DY, et al. (2012) Exome Sequencing Identifies Rare Deleterious Mutations in DNA Repair Genes FANCC and BLM as Potential Breast Cancer Susceptibility Alleles. PLoS Genet 8: e1002894.
[18]
Zhang SQ, Jiang T, Li M, Zhang X, Ren YQ, et al. (2012) Exome sequencing identifies MVK mutations in disseminated superficial actinic porokeratosis. Nat Genet 44: 1156–1160.
[19]
Lind T, Tufaro F, McCormick C, Lindahl U, Lidholt K (1998) The putative tumor suppressors EXT1 and EXT2 are glycosyltransferases required for the biosynthesis of heparan sulfate. J Biol Chem 273: 26265–26268.
[20]
McCormick C, Duncan G, Goutsos KT, Tufaro F (2000) The putative tumor suppressors EXT1 and EXT2 form a stable complex that accumulates in the Golgi apparatus and catalyzes the synthesis of heparan sulfate. Proc Natl Acad Sci U S A 97: 668–673.
[21]
Duncan G, McCormick C, Tufaro F (2001) The link between heparan sulfate and hereditary bone disease: finding a function for the EXT family of putative tumor suppressor proteins. J Clin Invest 108: 511–516.
[22]
Busse M, Feta A, Presto J, Wilen M, Gronning M, et al. (2007) Contribution of EXT1, EXT2, and EXTL3 to heparan sulfate chain elongation. J Biol Chem 282: 32802–32810.
[23]
Ornitz DM (2000) FGFs, heparan sulfate and FGFRs: complex interactions essential for development. Bioessays 22: 108–112.
[24]
Takada T, Katagiri T, Ifuku M, Morimura N, Kobayashi M, et al. (2003) Sulfated polysaccharides enhance the biological activities of bone morphogenetic proteins. J Biol Chem 278: 43229–43235.
[25]
Bellaiche Y, The I, Perrimon N (1998) Tout-velu is a Drosophila homologue of the putative tumour suppressor EXT-1 and is needed for Hh diffusion. Nature 394: 85–88.
[26]
Koziel L, Kunath M, Kelly OG, Vortkamp A (2004) Ext1-dependent heparan sulfate regulates the range of Ihh signaling during endochondral ossification. Dev Cell 6: 801–813.
[27]
Bornemann DJ, Duncan JE, Staatz W, Selleck S, Warrior R (2004) Abrogation of heparan sulfate synthesis in Drosophila disrupts the Wingless, Hedgehog and Decapentaplegic signaling pathways. Development 131: 1927–1938.
[28]
Wei G, Bai X, Gabb MM, Bame KJ, Koshy TI, et al. (2000) Location of the glucuronosyltransferase domain in the heparan sulfate copolymerase EXT1 by analysis of Chinese hamster ovary cell mutants. J Biol Chem 275: 27733–27740.
[29]
Bernard MA, Hall CE, Hogue DA, Cole WG, Scott A, et al. (2001) Diminished levels of the putative tumor suppressor proteins EXT1 and EXT2 in exostosis chondrocytes. Cell Motil Cytoskeleton 48: 149–162.
[30]
Wuyts W, Van Hul W, De Boulle K, Hendrickx J, Bakker E, et al. (1998) Mutations in the EXT1 and EXT2 genes in hereditary multiple exostoses. Am J Hum Genet 62: 346–354.
[31]
Cheung PK, McCormick C, Crawford BE, Esko JD, Tufaro F, et al. (2001) Etiological point mutations in the hereditary multiple exostoses gene EXT1: a functional analysis of heparan sulfate polymerase activity. Am J Hum Genet 69: 55–66.
[32]
Wang JL, Yang X, Xia K, Hu ZM, Weng L, et al. (2010) TGM6 identified as a novel causative gene of spinocerebellar ataxias using exome sequencing. Brain 133: 3510–3518.
